siranoush manoukian

List of Publications by Year
in descending order

		36691	18400
142	16,292	53	124
papers	citations	h-index	g-index

144	144	144	19105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
3	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
4	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
5	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
6	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
7	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
8	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461
9	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
10	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
11	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research, 2010, 70, 2789-2798.	0.4	365
12	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology, 2007, 242, 698-715.	3.6	324
13	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
14	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022.	2.3	306
15	Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	289
16	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
17	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
18	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244

#	Article	IF	Citations
19	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
20	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute, 2008, 100, 1361-1367.	3.0	179
21	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
22	Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. Journal of Clinical Oncology, 2008, 26, 1093-1097.	0.8	161
23	Evaluation of SNPs inmiR-146a,miR196a2andmiR-499as low-penetrance alleles in German and Italian familial breast cancer cases. Human Mutation, 2010, 31, E1052-E1057.	1.1	147
24	Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers. International Journal of Gynecological Pathology, 2004, 23, 35-40.	0.9	135
25	Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer, 2008, 99, 371-374.	2.9	132
26	Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions. American Journal of Surgical Pathology, 2006, 30, 1222-1230.	2.1	130
27	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
28	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
29	Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis. Cancer Research, 2007, 67, 1494-1501.	0.4	110
30	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
31	19p13.1 Is a Triple-Negativeâ€“Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.4	100
32	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
33	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
34	Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. PLoS ONE, 2013, 8, e55681.	1.1	95
35	No evidence that protein truncating variants inBRIP1are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	1.5	94
36	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93

#	Article	IF	Citations
37	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R42.	2.2	92
38	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
39	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
40	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a caseâ€“control study. Cancer Causes and Control, 2008, 19, 1111-1119.	0.8	87
41	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	1.5	85
42	Classification of BRCA1 missense variants of unknown clinical significance. Journal of Medical Genetics, 2005, 42, 138-146.	1.5	79
43	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
44	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
45	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Research and Treatment, 2012, 134, 411-418.	1.1	73
46	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
47	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
48	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
49	Comparative In Vitro and In Silico Analyses of Variants in Splicing Regions of BRCA1 and BRCA2 Genes and Characterization of Novel Pathogenic Mutations. PLoS ONE, 2013, 8, e57173.	1.1	64
50	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	1.1	63
51	miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer. PLoS ONE, 2014, 9, e87039.	1.1	59
52	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment, 2013, 142, 177-185.	1.1	57
53	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
54	Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. Journal of Investigative Dermatology, 2009, 129, 1759-1768.	0.3	54

#	Article	IF	Citations
55	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
56	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
57	Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620.	1.5	49
58	Identification of fifteen novel germline variants in theBRCA13â€²UTR reveals a variant in a breast cancer case that introduces a functionalmiR-103target site. Human Mutation, 2012, 33, 1665-1675.	1.1	49
59	A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6. Cancer Research, 2007, 67, 9134-9141.	0.4	47
60	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
61	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
62	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	0.6	45
63	A Comparison of Bilateral Breast Cancers in BRCA Carriers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1534-1538.	1.1	44
64	Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. European Journal of Cancer, 2007, 43, 601-606.	1.3	44
65	BRCA1 p.Val1688del Is a Deleterious Mutation That Recurs in Breast and Ovarian Cancer Families From Northeast Italy. Journal of Clinical Oncology, 2008, 26, 26-31.	0.8	44
66	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
67	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
68	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Human Mutation, 2004, 24, 100-101.	1.1	39
69	Indications for breast magnetic resonance imaging. Consensus document â€œAttualitÃ in senologiaâ€, Florence 2007. Radiologia Medica, 2008, 113, 1085-1095.	4.7	38
70	Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 660, 1-11.	0.4	38
71	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
72	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	0.5	38

#	Article	IF	Citations
73	PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Research and Treatment, 2011, 126, 825-828.	1.1	37
74	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
75	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 146, 421-427.	1.1	35
76	First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer, 2013, 13, 46.	1.1	34
77	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
78	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
79	Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. Breast Cancer Research and Treatment, 2013, 138, 861-868.	1.1	32
80	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332.	0.6	32
81	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
82	Wholeâ€exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer, 2017, 123, 210-218.	2.0	31
83	Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. Journal of Human Genetics, 2006, 51, 209-216.	1.1	29
84	The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Research and Treatment, 2012, 133, 805-807.	1.1	28
85	The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. Clinical Genetics, 2014, 85, 7-15.	1.0	28
86	Triple-Negative versus Nonâ€“Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study. Clinical Cancer Research, 2016, 22, 895-904.	3.2	28
87	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Research and Treatment, 2007, 103, 29-36.	1.1	27
88	Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Research and Treatment, 2010, 124, 251-258.	1.1	27
89	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€“Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
90	Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Familial Cancer, 2011, 10, 521-528.	0.9	27

#	Article	IF	Citations
91	Characterization of a cytogenetic 17q11.2 deletion in an NF1 patient with a contiguous gene syndrome. Human Genetics, 1996, 98, 646-650.	1.8	26
92	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
93	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
94	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. Genetics in Medicine, 2014, 16, 688-694.	1.1	25
95	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. European Journal of Cancer, 2015, 51, 2289-2295.	1.3	25
96	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24
97	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer, 2016, 114, 1160-1164.	2.9	24
98	Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1. PLoS ONE, 2014, 9, e86924.	1.1	24
99	SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis, 2009, 30, 544-545.	1.3	23
100	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
101	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. Breast Cancer Research and Treatment, 2003, 81, 71-79.	1.1	22
102	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
103	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
104	Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. European Journal of Internal Medicine, 2016, 32, 65-71.	1.0	21
105	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21
106	The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detection and Prevention, 2008, 32, 140-143.	2.1	20
107	Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Research and Treatment, 2009, 113, 607-608.	1.1	20
108	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460.	2.9	19

#	Article	IF	Citations
109	HMGA1 protein expression in familial breast carcinoma patients. European Journal of Cancer, 2010, 46, 332-339.	1.3	19
110	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	1.6	19
111	A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. BMC Medical Genetics, 2014, 15, 59.	2.1	18
112	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
113	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	1.1	17
114	Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Modern Pathology, 2008, 21, 1262-1270.	2.9	16
115	No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Research and Treatment, 2011, 126, 235-239.	1.1	16
116	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
117	A randomized controlled trial of diet and physical activity in BRCA mutation carriers. Familial Cancer, 2014, 13, 181-187.	0.9	14
118	Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations. Breast Cancer Research and Treatment, 2011, 130, 207-215.	1.1	13
119	The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. Journal of Medical Genetics, 2011, 48, 703-704.	1.5	13
120	Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Research and Treatment, 2011, 129, 947-954.	1.1	12
121	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
122	Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Familial Cancer, 2015, 14, 117-128.	0.9	12
123	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2011, 125, 855-860.	1.1	11
124	X chromosome inactivation pattern in BRCA gene mutation carriers. European Journal of Cancer, 2013, 49, 1136-1141.	1.3	11
125	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	1.1	11
126	Sequencing Analysis of SLX4/FANCP Gene in Italian Familial Breast Cancer Cases. PLoS ONE, 2012, 7, e31038.	1.1	10

#	Article	IF	Citations
127	Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors. Scientific Reports, 2015, 5, 15454.	1.6	10
128	Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. Melanoma Research, 2008, 18, 431-437.	0.6	9
129	Kaufman oculocerebrofacial syndrome in a girl of 15 years. American Journal of Medical Genetics Part A, 1995, 58, 21-23.	2.4	8
130	An unusual BRCA2 allele carrying two splice site mutations. Annals of Oncology, 2009, 20, 1143-1144.	0.6	8
131	Prenatal testing in a fetus at risk for autosomal dominant polycystic kidney disese and autosomal recessive junctional epidermolysis bullosa with pyloric atresia. American Journal of Medical Genetics Part A, 1993, 47, 1225-1230.	2.4	7
132	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
133	Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy. Breast Cancer Research and Treatment, 2014, 148, 623-628.	1.1	7
134	Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. PLoS ONE, 2017, 12, e0171663.	1.1	7
135	A BRCA1 promoter variant (rs11655505) and breast cancer risk. Journal of Medical Genetics, 2010, 47, 268-270.	1.5	6
136	Bilateral preaxial polydactyly in a WAGR syndrome patient. American Journal of Medical Genetics, Part A, 2005, 134A, 426-429.	0.7	5
137	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 2011, 105, 1934-1939.	2.9	4
138	A Targeted Approach to Genetic Counseling in Breast Cancer Patients: The Experience of an Italian Local Project. Tumori, 2016, 102, 45-50.	0.6	4
139	Re: Molecular Basis for Estrogen Receptor Â Deficiency in BRCA1-Linked Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 752-753.	3.0	2
140	Cardio-Oncology. Journal of the American College of Cardiology, 2016, 68, 1921-1923.	1.2	2
141	What is specific in hereditary breast cancer? High T2 signal intensity as a new semeiotic pattern?. European Journal of Radiology, 2012, 81, S165-S170.	1.2	1
142	Malignant salivary gland tumours in families with breast cancer susceptibility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 221-226.	1.4	0